Sirolimus - An Overview

Drug Overview

Sirolimus is an immunosuppressant used to prevent organ rejection post-transplantation. It inhibits mTOR (Mammalian target of rapamycin) and suppresses T lymphocyte activation. Common side effects include increased infection risk, elevated cholesterol, and mouth-sores. Regular monitoring of drug levels and potential adverse effects is crucial during treatment. Sirolimus is often used in combination with other immunosuppressants. The FDA (U.S. Food and Drug Administration) approved it as an oral tablet on September 15, 1999.

For the Patients:

What Are the Clinical Indications for Sirolimus?

Sirolimus is primarily indicated for the prevention of organ rejection in patients who have received kidney transplants. It is also combined with other immunosuppressants in liver and heart transplant recipients.

What Is the Dosage of Sirolimus?

Take orally once daily, consistently, with or without food. Administer the first dose promptly post-transplantation and four hours following Cyclosporine A (CsA) administration.

What Are the Things to Inform the Doctor Before Taking the Drug?

The patient must inform the doctor if they are on other medications before starting this drug.

They should also inform them about the below-mentioned conditions:

• Pregnancy.

• Heart disease.

• Liver disease.

• Migraines (headaches with severe throbbing or pulsating pain).

• Seizures (sudden, uncontrolled muscular movements).

• Kidney diseases.

• Stroke (blockage of blood supply to the brain).

• Cancer.

• Diabetes (increased levels of blood sugar due to insulin dysfunction).

How Is Sirolimus Administered?

Sirolimus is typically administered orally as a tablet or as an oral solution. It is taken consistently once a day and can be taken with or without food. The initial dose should be administered immediately after transplantation and four hours following Cyclosporine A (CsA) administration.

What Are the Side Effects of Sirolimus?

• Increased risk of infection.

• Elevated cholesterol and triglyceride levels.

• Mouth sores.

• Nausea and vomiting.

• Diarrhea.

• Rash.

• Swelling or fluid retention.

• High blood pressure.

• Bone marrow suppression leads to anemia (by destroying blood-forming cells in the bone marrow).

• Delayed wound healing.

• Interstitial lung disease (inflammation or scarring of lung tissue leading to breathing problems).

• Hepatotoxicity (liver damage).

Missed Dose:

• If a patient misses a dose of Sirolimus, they should take it as soon as they remember unless it is close to the next scheduled dose. In that case, they should skip the missed dose and continue their regular dosing schedule. It is important not to take a double dose to make up for a missed one.

• Consistency in medication timing helps maintain stable drug levels in the bloodstream, which is crucial for its effectiveness in preventing organ rejection. If the patient is still trying to figure out what to do, they should consult their healthcare provider or pharmacist for guidance.

Overdose:

A sirolimus tablet overdose may present with symptoms that include vomiting, nausea, lightheadedness, and drowsiness.

Storage:

Sirolimus is not absorbed through the skin, so no specific precautions are needed. However, if direct skin or mucous membrane contact occurs, thoroughly wash with soap and water and rinse the eyes with plain water.

For Doctors:

Indication:

Sirolimus is prescribed for preventing organ rejection in patients aged 13 years or older who have undergone renal transplantation. Therapeutic drug monitoring is advised for all patients on Sirolimus.

• For patients with low to moderate immunologic risk, initiating Sirolimus therapy alongside cyclosporine and corticosteroids is suggested. Cyclosporine should be discontinued two to four months post-transplantation.

• For patients at high immunologic risk, including black recipients and repeat renal transplant recipients who lost a previous graft due to immunological reasons, use Sirolimus in conjunction with cyclosporine and corticosteroids during the first year post-transplantation.

Dose:

The first dose of Sirolimus should be given promptly following transplantation. It is advised to take Sirolimus four hours after administering cyclosporine oral solution.

Dosing Considerations:

• Tablets of Sirolimus should not be crushed, chewed, or divided.

• Patients who cannot take tablets should receive the solution and be educated on its administration.

• Regular adjustments of Sirolimus doses based on non-steady-state concentrations may result in overdosing or underdosing due to its extended half-life.

• Following adjustment of the maintenance dose of Sirolimus, patients should maintain the new dose for a minimum of seven to 14 days before considering further adjustments based on concentration monitoring.

What Are the Pharmacological Aspects of Sirolimus?

Mechanism of Action

Sirolimus exerts its immunosuppressive effects primarily by inhibiting the mTOR (Mammalian target of rapamycin) pathway, a critical signaling pathway involved in cell growth, proliferation, and survival. By binding to the cytoplasmic protein FKBP-12, Sirolimus forms a complex that selectively inhibits mTOR, specifically mTOR complex 1 (mTORC1). This inhibition blocks downstream signaling events, ultimately suppressing the activation and proliferation of T lymphocytes, a key component of the immune response involved in organ rejection. Additionally, Sirolimus may interfere with the response of antigen-presenting cells and the production of cytokines, further dampening the immune response. By disrupting these signaling pathways, Sirolimus helps prevent the rejection of transplanted organs by the recipient's immune system.

Pharmacokinetics

• Absorption: Sirolimus is administered orally, typically as a tablet or solution. It is absorbed slowly and variably from the gastrointestinal tract after oral ingestion. The absorption rate can be affected by food intake and medication formulation factors. Peak plasma concentrations are typically reached within one to four hours after administration.

• Distribution: Sirolimus has a large volume, indicating extensive distribution throughout the body's tissues. It binds extensively to erythrocytes and plasma proteins, primarily albumin. This protein binding can affect its distribution and elimination from the body.

• Metabolism: Sirolimus undergoes extensive metabolism primarily in the liver, predominantly by the cytochrome P450 3A4 (CYP3A4) enzyme. This metabolic process involves the formation of various metabolites, some of which may contribute to the drug's pharmacological effects or toxicity.

• Elimination: Sirolimus and its metabolites are eliminated through hepatic metabolism. Metabolites are excreted in both feces and urine. Sirolimus's elimination half-life is prolonged, ranging from 30 to 60 hours. This extended half-life contributes to the drug's accumulation in the body with repeated dosing.

• Nonlinear Pharmacokinetics: Sirolimus exhibits nonlinear pharmacokinetics, meaning its clearance decreases as the dose increases. This nonlinear behavior is due to the saturation of metabolic pathways at higher doses, resulting in disproportionate increases in blood concentrations compared to dose increases. As a result, careful monitoring of blood levels and dosage adjustments are necessary to maintain therapeutic concentrations.

• Drug Interactions: Sirolimus is susceptible to drug interactions due to its metabolism by CYP3A4. Concomitant medications that induce or inhibit CYP3A4 activity can affect Sirolimus metabolism and blood concentrations. Additionally, drugs that compete for protein-binding sites may alter the distribution of Sirolimus in the bloodstream.

Pharmacodynamics:

• Immunosuppressive Effects: By targeting the mTOR pathway, Sirolimus exerts potent immunosuppressive effects, primarily on T lymphocytes, which play a central role in the immune response. Sirolimus inhibits T cells' activation, proliferation, and differentiation, attenuating cellular and humoral immune responses. This immunosuppressive action helps prevent the rejection of transplanted organs by suppressing the recipient's immune system.

• Antiproliferative Effects: In addition to its immunosuppressive properties, Sirolimus exhibits antiproliferative effects on various cell types. These effects contribute to the drug's utility in preventing restenosis following coronary artery stenting and in treating certain proliferative disorders, such as lymphangioleiomyomatosis.

• Angiogenesis Inhibition: Sirolimus has been shown to inhibit angiogenesis, the process by which new blood vessels form from pre-existing vessels. Sirolimus interferes with forming new blood vessels, which may contribute to its efficacy in treating certain vascular proliferative disorders and solid tumors.

• Antitumor Effects: Beyond its immunosuppressive and antiproliferative actions, Sirolimus exhibits direct antitumor effects in certain cancers. These findings have led to investigations into using Sirolimus and related mTOR inhibitors as potential anticancer therapies.

• Metabolic Effects: Sirolimus may also exert metabolic effects, including lipid metabolism and glucose homeostasis alterations. Treatment with Sirolimus has been associated with dyslipidemia, including increases in cholesterol and triglyceride levels. Additionally, Sirolimus may impair glucose tolerance and insulin sensitivity, potentially leading to hyperglycemia and diabetes mellitus.

Clinical Studies and Efficacy:

• The safety and effectiveness of Sirolimus Oral Solution in preventing organ rejection after renal transplantation were evaluated in two double-blind, randomized, multicenter trials.

• These trials compared two doses of Sirolimus Oral Solution (two milligrams and five milligrams, once daily) with Azathioprine (Study 1) or placebo (Study 2) in combination with Cyclosporine and Corticosteroids.

• Study one, conducted in the United States, enrolled 719 patients post-transplantation, while study two, conducted across multiple countries, enrolled 576 patients pre-transplantation.

• The primary endpoint in both studies was the rate of efficacy failure in the first six months after transplantation, defined as the first occurrence of acute rejection (confirmed by biopsy), graft loss, or death.

• Patients who experienced biopsy-proven acute rejection had a lower mean glomerular filtration rate (GFR) at one-year post-transplantation than those who did not.

• Renal function should be regularly monitored, and adjustments to the immunosuppressive regimen should be considered.

What Are the Contraindications of Sirolimus?

Sirolimus should not be administered to individuals with a known hypersensitivity.

Warnings and Precautions:

• Increased Risk of Infection and Lymphoma Development:

  • Immunosuppression with Sirolimus may increase susceptibility to infections and the development of lymphoma and other malignancies, particularly skin cancers.

  • Oversuppression of the immune system can also lead to increased susceptibility to infections, including opportunistic infections such as tuberculosis, which can be fatal.

• Liver Transplantation:

  • Sirolimus is not recommended for use in liver transplant patients due to associated adverse outcomes, including excess mortality, graft loss, and hepatic artery thrombosis (HAT).

  • Studies have shown increased mortality and graft loss with Sirolimus use in liver transplant patients, especially when combined with tacrolimus.

  • Sirolimus use in combination with cyclosporine or tacrolimus has been associated with an increased risk of HAT, often leading to graft loss or death.

• Lung Transplantation:

  • Sirolimus use is not recommended for lung transplant patients due to reported cases of bronchial anastomotic dehiscence, some of which were fatal.

• Hypersensitivity Reactions:

  • The administration of Sirolimus has been linked to hypersensitivity responses such as anaphylactic reactions, angioedema, and hypersensitivity vasculitis.

• Angioedema:

  • Sirolimus use has been linked to the development of angioedema, especially when used concomitantly with other drugs known to cause angioedema, such as ACE inhibitors.

• Fluid Accumulation and Wound Healing:

  • Sirolimus use has been associated with impaired or delayed wound healing, including lymphocele and wound dehiscence.

  • Reports indicate fluid accumulation in patients receiving Sirolimus, such as peripheral edema, pleural effusion, and pericardial effusions.

• Hyperlipidemia:

  • Sirolimus-treated patients may experience increased serum cholesterol and triglyceride levels, necessitating monitoring and potential intervention with lipid-lowering agents.

• Renal Function:

  • Renal function should be closely monitored in patients receiving Sirolimus, especially when co-administered with Cyclosporine, as it may lead to deterioration of renal function.

• Proteinuria:

  • Periodic monitoring of urinary protein excretion is recommended due to the increased proteinuria observed with Sirolimus use, especially following conversion from calcineurin inhibitors.

• Latent Viral Infections:

  • Immunosuppressed patients, including those receiving Sirolimus, are at increased risk of opportunistic infections, including BK virus-associated nephropathy and progressive multifocal leukoencephalopathy (PML).

• Interstitial Lung Disease:

  • Sirolimus use has been associated with interstitial lung disease, including pneumonitis and pulmonary fibrosis, with some cases proving fatal.

• Increased Risk of Calcineurin Inhibitor-Induced HUS/TTP/TMA:

  • Co-administration of Sirolimus with calcineurin inhibitors may increase the risk of hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, or thrombotic microangiopathy (HUS/TTP/TMA).

• Antimicrobial Prophylaxis:

  • Prophylaxis against Pneumocystis carinii pneumonia and cytomegalovirus is recommended following transplantation.

• Assay for Sirolimus Therapeutic Drug Monitoring:

  • Various methodologies are used to measure Sirolimus concentrations, and results may differ between assays.

• Skin Cancer Events:

  • Immunosuppressed patients, including those receiving Sirolimus, are at increased risk of skin cancer, necessitating precautions against sun exposure.

• Interaction with Strong Inhibitors and Inducers of CYP3A4 and P-gp:

  • Co-administration of Sirolimus with strong CYP3A4 and/or P-gp inhibitors or inducers is not recommended due to potential interactions.

Specific Considerations

• Pregnancy:

  • Sirolimus is classified as pregnancy category C, as it has shown embryo or fetotoxic effects in rats at doses approximately 0.2 to 0.5 times the human dose.

  • While no teratogenic effects were observed, effective contraception should be used before, during, and for 12 weeks after Sirolimus therapy.

  • Sirolimus should be used during pregnancy only if the potential benefits outweigh the potential risks to the embryo or fetus.

• Nursing Mothers:

  • While lactating rats excrete Sirolimus in minimal quantities in their milk, its excretion in human milk remains unspecified.

  • Given the potential for adverse effects in nursing infants, it is advisable to weigh the decision between discontinuing nursing or discontinuing Sirolimus therapy, considering the significance of the medication to the mother.

• Pediatric Use:

  • The safety and efficacy of Sirolimus in pediatric patients under 13 years of age have not been established.

  • However, Sirolimus Oral Solution and Tablets have been deemed safe and effective in children aged 13 years and older with low to moderate immunologic risk.

  • Pediatric and adolescent renal transplant patients at high immunologic risk showed a higher incidence of lipid abnormalities and inhibitors, and renal function decline may occur when Sirolimus is used alongside calcineurin inhibitors and corticosteroids.

• Geriatric Use:

  • Clinical trials lacked an adequate representation of patients aged 65 and older to ascertain variations in response compared to younger patients.

  • It is advisable to exercise caution when selecting doses for elderly patients, initiating treatment at the lower end of the dosage spectrum due to possible age-related alterations in hepatic or cardiac function.

• Patients with Hepatic Impairment:

  • Patients with hepatic impairment should have their maintenance dose of Sirolimus decreased following the dosage and administration instructions.

• Patients with Renal Impairment:

  • There is no need for dosage adjustment in patients with renal impairment when utilizing Sirolimus.